Serometrix - Predictive Drug Discovery

A unique merger of science and product development, Serometrix is a flexible biotech drug discovery company made up of seasoned professionals that are changing the way drug discovery is performed - both scientifically and commercially.

A privately funded company founded in 2004, the company has been built around a proprietary in silico drug discovery platform developed by the founders. The company is developing paradigm shifting partnerships and collaborations that provide creative solutions to solve industry pipeline challenges.

The Serometrix team provides a diverse range of expertise encompassing disease related biology, medicinal chemistry, molecular biophysics and modeling, and proprietary software and hardware development. Our unique cross-disciplinary approach provides effective and rational drug discovery and optimization strategies.

Mr. Michael Muehlemann, CEO/CTO

A successful serial entrepreneur and technology manager with experience in theoretical and experimental sciences, research, product development, and commercialization. His background includes business development, international sales, and market development. Mr. Muehlemann holds BS and MS degrees in Physics from the University of Missouri.

Mr. Kyle Monroe, EVP Corporate Development

Mr. Monroe has a background in investment banking, license deal structuring, and corporate finance. He founded Peregrine Capital Partners, LLC, a boutique investment banking firm focused on high value-added financial and consulting services for public and privately owned middle market companies. Mr. Monroe has an MBA from the S.C. Johnson Graduate School of Management at Cornell University, and holds a BS from the School of Management at SUNY Buffalo.

Dr. Margaret Reece, Chief Scientific Officer

Dr. Reece has an extensive background in physiology, endocrinology, and molecular biology. She has solid experience in both clinical medicine and laboratory research including cell science, biotechnology, medicine, biochemistry, and reproductive biology. She has experience with IRB projects, clinical trial monitoring, and FDA/TPD regulations regarding drug development. Dr. Reece holds a PhD from the University of California, Davis.

Dr. Bernard Poiesz, MD

Director of Oncology, SUNY Upstate Medical Hospital, Syracuse, NY. An active researcher and clinician with a history of successful commercial partnerships. Played pivotal role in the commercialization of PCR technology for HIV diagnostics at Cetus Corporation (now Chiron). Nobel Prize was awarded for this technology, which developed into a multibillion dollar market.

Dr. Irwin Frank, MD

Medical Director, University of Rochester. Previous medical director and senior director of Strong Memorial Hospital, and senior associate dean for clinical affairs at the School of Medicine and Dentistry. Dr. Frank has been a clinician and investigator involved in numerous medical research studies, and has over 50 publications. He was former president of the American Urological Association and chair of the Department of Urology at University of Rochester.

Dr. George Anstadt, MD

Medical Director of Concentra Inc. Serial entrepreneur with relationships at Eastman Pharmaceuticals, Myotech (cardiac assist), Lucid (health imaging), PeerPlace and RHIG (informatics), Eli Lilly, Ortho Biotech, Schering, AstraZeneca, Metracomp, American Medical Association, American College Preventive Medicine, University of Rochester, HPCA (wellness), and Simon and Kellogg School of Business.

Mr. Carl Foster, Business Development

Currently EVP Business Development at Cempra Pharmaceuticals. Previously CEO of Jurilab. Held VP-level positions at Nanogen, King Pharmaceuticals, Oxford GlycoSciences & Praecis Pharmaceuticals. Sales, marketing, product development, and business development experience at Merck and Astra Merck. Managing Director at Ferghana Partners, an international investment banking group in New York. MBA in Marketing and MS in Biochemistry from the University of Kansas where he conducted neurochemical research.

Mr. Vic Nole, Operations

Mr. Nole has over 20 years of Life Sciences management experience as President of Invitrogen's GIBCO cell culture products division, as VP of Operations for Life Technologies Inc., and as VP of Business Development for United Biochemicals. He founded Buffalo BioSciences (a management services business) and the NutriCyte Corporation (a custom cell culture products business servicing drug discovery). Mr. Nole holds a BS in Biology from the University at Buffalo and an MBA from Canisius College.

We seek motivated scientists and management professionals that have a strong desire to dramatically change the efficiency with which life saving pharmaceuticals are discovered and developed. Individuals with the drive to play a substantial role in the success of this company are encouraged to review the following opportunities:

We seek experienced medicinal chemists with proven molecular modeling and ligand optimization experience using one or more industry standard tools including Schrodinger Glide, MolSoft ICM, or CCDC Gold. Must be able to work independently on specific projects, yet be active members in specialized teams.

We seek a Neurophysiologist program leader with preclinical drug development experience, including neuropharmacology. Key areas of therapeutic interest include neurotrophic factors and peripheral pain pathways. Must be able to lead programs in these areas of therapeutic discovery.

We seek an experienced cancer immunologist, particularly in the area of the immune system's role in, and response to, metastases. Emphasis on metastatic tumor cell-immune cell interactions, and mechanistic pathways relating to regulation of cell-mediated immunity. Must work well in a team environment, including other cancer biologists and molecular modelers. Must have a track record of results based projects as well as pure scientific accomplishments.